Exhibit 8.1 |
At December 31, 2010 | Country | Percentage of voting share capital held (1) | Principal activity |
UK | |||
AstraZeneca UK Limited | England | 100 | Research and development, manufacturing, marketing |
AstraZeneca Treasury Limited | England | 100 | Treasury |
Continental Europe | |||
NV AstraZeneca SA | Belgium | 100 | Marketing |
AstraZeneca Dunkerque Production SCS | France | 95 | Manufacturing |
AstraZeneca SAS | France | 100 | Research, manufacturing, marketing |
Novexel SA | France | 100 | Research |
AstraZeneca GmbH | Germany | 100 | Development, manufacturing, marketing |
AstraZeneca Holding GmbH | Germany | 100 | Manufacturing, marketing |
AstraZeneca SpA | Italy | 100 | Marketing |
AstraZeneca Farmaceutica Spain SA | Spain | 100 | Marketing |
AstraZeneca AB | Sweden | 100 | Research and development, manufacturing, marketing |
AstraZeneca BV | The Netherlands | 100 | Marketing |
The Americas | |||
AstraZeneca Canada Inc. | Canada | 100 | Research, marketing |
AZ Reinsurance Limited | Cayman Islands | 100 | Insurance and reinsurance underwriting |
IPR Pharmaceuticals Inc. | Puerto Rico | 100 | Development, manufacturing, marketing |
AstraZeneca LP | US | 99 | Research and development, manufacturing, marketing |
AstraZeneca Pharmaceuticals LP | US | 100 | Research and development, manufacturing, marketing |
Zeneca Holdings Inc. | US | 100 | Manufacturing, marketing |
MedImmune, LLC | US | 100 | Research and development, manufacturing, marketing |
Asia, Africa & Australasia | |||
AstraZeneca Pty Limited | Australia | 100 | Development, manufacturing, marketing |
AstraZeneca Pharmaceuticals Co., Limited | China | 100 | Research and development, manufacturing, marketing |
AstraZeneca KK | Japan | 80 | Manufacturing, marketing |
(1) All shares are held indirectly. |
The companies and other entities listed above are those whose results or financial position principally affected the figures shown in the Financial Statements of AstraZeneca PLC and its subsidiaries (the “Group”). A full list of subsidiaries, joint ventures and associates will be annexed to AstraZeneca PLC’s next annual return filed with the Registrar of Companies. The country of registration or incorporation is stated alongside each company. The accounting year ends of subsidiaries and associates are December 31, except for Aptium Oncology, Inc. which, owing to local conditions and to avoid undue delay in the preparation of the Financial Statements, is November 30. The Company operates through 254 subsidiaries worldwide. Products are manufactured in 16 countries worldwide and are sold in over 100 countries. The Group Financial Statements consolidate the Financial Statements of the Company and its subsidiaries at December 31, 2010. |